Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received two drug license suspension orders from the Telangana Drugs Control Administration. The first order suspends the license of the Karambakkam store for three days, with a potential revenue loss of about Rs 1.59 lakhs. The second order suspends the K K Road, Suryapet store for seven days, with a potential revenue loss of about Rs 1.80 lakhs. Both suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940. The orders were received on June 19, 2025. Combined potential revenue impact is roughly Rs 3.39 lakhs, which is negligible relative to Medplus's overall operations.
The financial impact is minimal (under Rs 4 lakhs combined) and confined to two stores in Telangana, so this is unlikely to move the stock. However, repeated license actions could raise compliance concerns if they become a pattern across the chain.